Financial Daily from THE HINDU group of publications
Wednesday, Sep 29, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements


Biocon begins phase-II trials of cancer drug

Our Bureau

Bangalore , Sept. 28

BIOCON Ltd today announced that it has commenced phase-II clinical trials of its oncology drug TheraCIM (h-R3).

The drug is a humanised monoclonal antibody (MAb) used in the treatment of head and neck cancers and the company has received all necessary pre-trial approvals from the authorities concerned. The data is posted on the company Web site, it said in a release.

TheraCIM is one of the eight products being developed for the Indian market under Biocon Biopharmaceuticals, the venture with the Cuban R&D partner CIMAB. It has already received a fast-track approval from the National Regulatory Authority of Cuba and `orphan drug' status from the European Agency for the Evaluation of Medicinal Products to treat cancer patients.

MAbs, considered future therapeutics, attack cancer-causing receptors and form a new line of cancer treatment along with radiotherapy and chemotherapy.

Once the tests are through, Biocon Biopharmaceuticals will produce the MAbs in its large biological facility, expected to be ready in the second half of 2005.

Ms Kiran Mazumdar-Shaw, Biocon CMD, said, the development "marks a substantial advancement in Biocon's recombinant bio-therapeutic portfolio and brings us closer to commercialising the first such proprietary product."

Worldwide, head and neck cancers have a high incidence of half a million new cases annually, with nearly 2.5 lakh deaths.

More Stories on : Announcements | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Zee Tele gets nod to launch sports channel


Biocon begins phase-II trials of cancer drug
D-Link AGM okays dividend
Pilani Investments' AGM not to be an all-Birla affair
Zee has not met eligibility criteria: ESPN-Star
`BPL dispute will be resolved amicably'
Halcyon takeover: Kerala HC declines stay
BHEL net profit rises 48 pc to Rs 658 cr — To pay 60 per cent
Global brewers keen on UB stake: Mallya
Elder Pharma gets nod to sell stake to Italian co
Axles India to put up Rs 16-cr plant for Dana Corp supplies
Shantha Biotech vaccine plant inaugurated
McPhar, Alcock join hands for oil, mineral surveys
SAIL, Kudremukh in pact
Welcome bags 5 more hotels
Deepak Fertilizers plans specialty mall in Pune
Hyundai upbeat on response to Getz
Ruchi Soya sees 15% topline growth
Tata Chemicals in talks with IOC for LNG supply
Martial Rolland to take over reins of Nestle India
JB Chem gets new R&D V-P



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line